Funding
Series A · Biotech

Graph Therapeutics announces $5m Series A financing

Daphni, SquareOne, Merantix Capital and other participants backed the precision-medicine company.

Updated Oct 16, 2026By RoundOS Funding desk

Graph Therapeutics announced $5 million in Series A financing on June 22. Named participants included Daphni, SquareOne, Merantix Capital, NAVEC Investment Management, the Austrian Research Promotion Agency and Austria Wirtschaftsservice.

The company develops precision medicines for inflammatory and immune-mediated diseases using AI analysis of patient cells.

Funding history

Series A · This round$5M

Sources

  1. Graph Therapeuticsprojectstartups.com
  2. tech.eu

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related